申请人:HUTCHISON MEDIPHARMA LIMITED
公开号:US10208066B2
公开(公告)日:2019-02-19
This disclosure provides novel imidazopyridazine compounds of formula (I) and pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a process for preparing them, and their practical effect in inhibiting PI3K and potential use in treating a disease responsive to inhibition of PI3K, for example, an inflammatory disease, autoimmune disease or cancer.
本公开提供了新颖的式(I)咪唑哒嗪化合物及其药用可接受盐、含有它们的药物组合物、制备它们的工艺,以及它们在抑制PI3K方面的实际效果和在治疗对抑制PI3K有反应的疾病(例如炎症性疾病、自身免疫性疾病或癌症)中的潜在用途。